Stock Research: Insulet

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Insulet

NSQ:PODD US45784P1012
22
  • Value
    16
  • Growth
    47
  • Safety
    Safety
    53
  • Combined
    17
  • Sentiment
    57
  • 360° View
    360° View
    22
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Insulet Corporation is a medical device company specializing in continuous insulin delivery systems. It operates in the medical device industry, with its primary product being the Omnipod System. The company serves people with insulin-dependent diabetes and also produces pods for Amgen's Neulasta Onpro kit. In the last fiscal year, the company had a market cap of $20,451 million, profits of $1,446 million, revenue of $2,072 million, and 3900 employees.

more

ANALYSIS: With an Obermatt 360° View of 22 (better than 22% compared with alternatives), overall professional sentiment and financial characteristics for the stock Insulet are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Insulet. The consolidated Sentiment Rank has a good rank of 57, which means that professional investors are more optimistic about the stock than for 57% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 53 or better than 53% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 16, meaning that the share price of Insulet is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 47. ...read more

more
Index
NASDAQ
D.J. US Health Care
D.J. US Medical Equipment
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 1 4 1
Growth
47 67 71 65
Safety
Safety
53 26 4 16
Sentiment
57 90 90 16
360° View
360° View
22 46 27 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
59 80 64 14
Opinions Change
16 50 64 54
Pro Holdings
n/a 88 85 48
Market Pulse
50 69 74 21
Sentiment
57 90 90 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 1 4 1
Growth
47 67 71 65
Safety Safety
53 26 4 16
Combined
17 4 4 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
45 11 18 9
Price vs. Earnings (P/E)
17 9 19 10
Price vs. Book (P/B)
23 8 1 7
Dividend Yield
1 1 1 1
Value
16 1 4 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
82 81 73 45
Profit Growth
82 65 85 70
Capital Growth
9 19 46 69
Stock Returns
26 83 43 61
Growth
47 67 71 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
48 15 6 15
Refinancing
44 23 9 15
Liquidity
76 81 74 72
Safety Safety
53 26 4 16

Similar Stocks

Discover high‑ranked alternatives to Insulet and broaden your portfolio horizons.

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: